DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA408749
Title:
Premenopausal Levels of Circulating Insulin-Like Growth Factor I and the Risk of Post-Menopausal Breast Cancer: A Population-Based, Nested Case-Control Study
Descriptive Note:
Annual rept. 15 May 2001-14 May 2002
Corporate Author:
JOHNS HOPKINS UNIV BALTIMORE MD SCHOOLOF HYGIENE AND PUBLIC HEALTH
Report Date:
2002-06-01
Pagination or Media Count:
5.0
Abstract:
High levels of circulating IGF-l may be a risk factor for breast cancer. Only one population-based epidemiologic study of IGF-l and breast cancer measured circulating IGF-l in serum drawn prior to diagnosis. For post-menopausal breast cancer cases, no association was found. However, these analyses did not include IGF-l measures from the pre-menopausal period when endogenous IGF-l exposure is naturally higher and, potentially, more predictive of breast cancer risk. This study is a nested case-control analysis of archived serum samples and existing questionnaire data from the CLUE studies. 5,290 women participated in the prospective CLUE studies -- 129 developed a first, incident invasive breast cancer between 1990 and 1998. Cases diagnosed premenopausally will be excluded. One control will be matched to each case on age, menopausal status, age at menopause, follow-up time, date of each blood draw. Samples will be sent to the lab of Dr. Michael Pollack at McGill University. Plasma IGF-l and IGFBP-3 concentrations will be determined by enzyme-linked immunoabsorbent assay ELISA . Statistical analyses will 1 estimate the association between premenopausal IGF-l levels with and without adjustment for IGFBP-3 on postmenopausal breast cancer risk and 2 determine whether this association differs from that for postmenopausal IGF-l levels.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
